Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.
Our transformative product candidates - best in class - Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology.
Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients. In order to fully exploit the potential of Immatics' product pipeline and technologies we invite others to join us on this exciting mission.